MAPT and Alzheimer disease: Therefore, the present study strengthens and further extends our previous results [57] showing that: (i) an interplay occurring between APP/Aβ misprocessing and post-translational modifications of endogenous murine tau is more likely to drive the AD-like neurodegeneration in APP-expressing Tg2576 animal model and (ii) reducing tau pathology via the Aβ pathway can be a good therapeutic strategy, both in the retina and brain.